AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00185679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS System
Description: The CliniMACS System is a cell selection device consisting of the following components:~1. Computer-controlled instrument;~2. Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~3. Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~4. Wash buffer
Study NCT00823056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: placebo
Study NCT00823056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: 0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
Study NCT00006461 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00006461 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional conformal radiation therapy
Study NCT02433418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubal flushing by Urografin®
Description: Women will have tubal flushing through HSG using water soluble media (Urographin ®)
Study NCT02433418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
Study NCT02200406 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Desvenlafaxine
Description: All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
Study NCT01528332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Relief Patch
Description: The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
Study NCT01528332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control PRP device
Description: The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
Study NCT00600080 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: contact lens worn daily for one week (first or second week depending on arm)
Study NCT00600080 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: Contact lens worn daily for one week (first or second week depending on arm)
Study NCT03338192 — intervention group
Intervention type: OTHER
Intervention: QST
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
Study NCT03621475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel restraint
Description: Use of a novel arm restraint
Study NCT01596010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol / 1 mg norethisterone acetate (NETA)
Description: A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
Study NCT01596010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg estradiol / 1 mg norethisterone acetate (NETA)
Description: A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
Study NCT03873077 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: local infiltration analgesia
Description: 10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
Study NCT04102306 — intervention group
Intervention type: OTHER
Intervention: reliability and validity construct of the TMIQ
Description: comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest
Study NCT01143376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity training
Description: high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
Study NCT01143376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short springs
Description: short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
Study NCT01143376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Study NCT00880919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine extended-release
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Study NCT00880919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Study NCT03774576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: Single doses of RO7017773
Study NCT03774576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Multiple doses of Itraconazole
Study NCT03439228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar brace
Description: 3 months of lumbar brace wear
Study NCT02910882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Description: PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy.
Study NCT02910882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen.
Study NCT02910882 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
Study NCT02815501 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samples
Description: for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
Study NCT02939287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1
Description: Add aprepitant to anti-emetic regimen
Study NCT02939287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine10 mg orally daily on Days -1,0,+1 and +2
Description: add olanzapine to anti-emetic regimen
Study NCT02939287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant plus Olanzapine
Description: add aprepitant and olanzapine to anti-emetic regimen
Study NCT02191735 — intervention group
Intervention type: DEVICE
Intervention: RAMP 200
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
Study NCT02191735 — intervention group
Intervention type: DEVICE
Intervention: RAMP Reader
Description: The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
Study NCT00329342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational ergonomic training
Description: Adequate postural habits in activities of daily living
Study NCT02016456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-Burst Stimulation
Description: At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
Study NCT02016456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency stimulation
Description: Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
Study NCT02101034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02101034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Study NCT01681056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autosuggestion for 30 days
Study NCT02253108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus eluting bioresorbable polymer stent
Study NCT02253108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus eluting bioresorbable polymer stent
Study NCT03336151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labelling Nutri-Score
Description: Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
Study NCT04773496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: instrumental description of the subject's center of gravity (COG) sway
Description: qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
Study NCT01907802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT01907802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01907802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT01907802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03225495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard implant
Description: Arm - Standard Implant: implant placement in combination with guided bone regeneration;
Study NCT03225495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra-narrow implant
Description: Arm - Ultra-narrow implant: implant placement without guided bone regeneration
Study NCT03234790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Air Exposure
Description: Exposure to Filtered air
Study NCT03234790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust Exposure
Description: Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
Study NCT04517552 — intervention group
Intervention type: DRUG
Intervention: [11C]-CS1P1
Description: Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
Study NCT00195858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic and resistance exercise
Description: aerobic and resistance exercise
Study NCT00195858 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic and resistance exercise
Description: aerobic and resistance exercise
Study NCT00861224 — intervention group
Intervention type: OTHER
Intervention: No Intervention for Observational Study
Description: No intervention was used on this protocol, as this was an observational study.
Study NCT03057977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: once daily
Study NCT03057977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT03207685 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Additional Seizure Monitoring
Description: Embrace could offer an additional layer of seizure monitoring
Study NCT02877563 — intervention group
Intervention type: OTHER
Intervention: Contrast ultrasound perfusion imaging of the limb
Description: Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
Study NCT03898947 — intervention group
Intervention type: PROCEDURE
Intervention: Diagnostic hysteroscopy and targeted endometrial biopsy
Description: Diagnostic hysteroscopy and targeted endometrial biopsy
Study NCT04028882 — intervention group
Intervention type: OTHER
Intervention: Signaling, metabolomic and transcriptomic analysis
Description: Signaling, metabolomic and transcriptomic analysis
Study NCT01399333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 Meal Replacement
Description: 4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
Study NCT01399333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 Protein Supplement
Description: 4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
Study NCT01399333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: 4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
Study NCT01438684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPh201
Description: 400 microliter s.c. twice a week for 3 months
Study NCT01438684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 400 microliter Saline solution s.c. twice a week for 3 months
Study NCT04616703 — intervention group
Intervention type: RADIATION
Intervention: CT imaging
Description: CT of abdomen
Study NCT00995020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Straight Wire Excision of Transformation Zone
Description: Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
Study NCT00995020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Loop Excision of Transformation Zone (cone biopsy)
Description: LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
Study NCT04279938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tinostamustinein
Description: Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
Study NCT04279938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
Study NCT04279938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV Q3W for 6 cycles
Study NCT02053038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFR
Description: Treatment guided by instantaneous wave-free ratio
Study NCT02053038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Description: Treatment guided by Fractional Flow Reserve
Study NCT04424797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Positioning
Description: Intervention is patient in prone positioning
Study NCT04424797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supine Positioning
Description: Intervention is patient in supine positioning
Study NCT02530853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture
Study NCT02530853 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: Laser acupuncture
Study NCT03325998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Hip Assist v1
Description: All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
Study NCT00091117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00091117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01121120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: 300mcg/kg/day, administered subcutaneously for up to 28 days
Study NCT01121120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300mcg/kg/day administered subcutaneously for up to 28 days
Study NCT00100854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00100854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00100854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly
Study NCT02271516 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 188Re-BMEDA-liposome
Description: EKG at baseline and in 24hours after administration
Study NCT01658150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isradipine
Description: Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
Study NCT01902056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One layer allograft
Description: The acellular dermal matrix was placed on the facial surface.
Study NCT01902056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two layer allograft
Description: The acellular dermal matrix was placed on the facial surface.
Study NCT03305354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI app intervention
Description: Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
Study NCT03305354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI app intervention
Description: Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
Study NCT03305354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity intervention
Description: Self-management guided motivation to increase physical activity by increasing daily step counts
Study NCT01679795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Study NCT01679795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01924351 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
Study NCT02918123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-CD Inj.
Description: Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
Study NCT01206777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
Study NCT02047292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA Corail PinnacleCoC28
Description: Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
Study NCT02047292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA Corail DeltaMotion36
Description: Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
Study NCT02047292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA Corail DeltaMotion40
Description: Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
Study NCT04261335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CL2020 cells
Description: 1.5 million or 15 million cells, IV on day 5 to 14 of birth